NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$75.79 +2.97 (+4.08 %)
(As of 01/16/2019 09:29 AM ET)
Previous Close$72.82
Today's Range$72.39 - $75.81
52-Week Range$61.39 - $127.77
Volume199,352 shs
Average Volume230,325 shs
Market Capitalization$1.41 billion
P/E Ratio21.78
Dividend YieldN/A
Beta0.99
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ENTA
CUSIPN/A
Phone617-607-0800

Debt

Current Ratio23.74
Quick Ratio23.74

Price-To-Earnings

Sales & Book Value

Annual Sales$206.63 million
Price / Sales7.12
Cash Flow$3.9556 per share
Price / Cash Flow19.16
Book Value$20.32 per share
Price / Book3.73

Profitability

Net Income$71.95 million
Net Margins34.82%
Return on Assets20.35%

Miscellaneous

Employees113
Market Cap$1.41 billion
OptionableOptionable

Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) released its earnings results on Monday, November, 26th. The biotechnology company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.06. The biotechnology company earned $67.20 million during the quarter, compared to analysts' expectations of $69.03 million. Enanta Pharmaceuticals had a return on equity of 21.56% and a net margin of 34.82%. The company's quarterly revenue was down 11.5% on a year-over-year basis. During the same period in the prior year, the company earned $1.86 earnings per share. View Enanta Pharmaceuticals' Earnings History.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for Enanta Pharmaceuticals.

What price target have analysts set for ENTA?

7 brokers have issued twelve-month price targets for Enanta Pharmaceuticals' stock. Their forecasts range from $80.00 to $133.00. On average, they expect Enanta Pharmaceuticals' stock price to reach $102.60 in the next year. This suggests a possible upside of 35.4% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

What is the consensus analysts' recommendation for Enanta Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

Has Enanta Pharmaceuticals been receiving favorable news coverage?

Media stories about ENTA stock have trended negative this week, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future.

Who are some of Enanta Pharmaceuticals' key competitors?

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the folowing people:
  • Dr. Jay R. Luly, Pres, CEO & Director (Age 62)
  • Dr. Yat Sun Or, Sr. VP-R&D and Chief Scientific Officer (Age 66)
  • Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 52)
  • Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 63)
  • Ms. Carol Miceli, Director of Investor Relations

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Navellier & Associates Inc (0.15%), Louisiana State Employees Retirement System (0.03%) and State of Alaska Department of Revenue (0.03%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathalie Adda, Paul J Mellett and Tim Ocain. View Institutional Ownership Trends for Enanta Pharmaceuticals.

Which institutional investors are selling Enanta Pharmaceuticals stock?

ENTA stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Jay R Luly, Nathalie Adda, Paul J Mellett and Tim Ocain. View Insider Buying and Selling for Enanta Pharmaceuticals.

Which institutional investors are buying Enanta Pharmaceuticals stock?

ENTA stock was bought by a variety of institutional investors in the last quarter, including Navellier & Associates Inc and State of Alaska Department of Revenue. View Insider Buying and Selling for Enanta Pharmaceuticals.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $75.79.

How big of a company is Enanta Pharmaceuticals?

Enanta Pharmaceuticals has a market capitalization of $1.41 billion and generates $206.63 million in revenue each year. The biotechnology company earns $71.95 million in net income (profit) each year or $3.48 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.

What is Enanta Pharmaceuticals' official website?

The official website for Enanta Pharmaceuticals is http://www.enanta.com.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]


MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  230 (Vote Outperform)
Underperform Votes:  248 (Vote Underperform)
Total Votes:  478
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Featured Article: Momentum Investing

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel